Prostate cancer cell vaccine transfected with 4-1BBL induces anti-tumor immunity in vitro.
- Author:
You-lin KUANG
1
;
Xiao-dong WENG
;
Xiu-heng LIU
;
Zhi-yuan CHEN
;
Heng-cheng ZHU
;
Bo-tao JIANG
Author Information
- Publication Type:Journal Article
- MeSH: 4-1BB Ligand; genetics; immunology; Animals; Cancer Vaccines; genetics; immunology; Cell Line, Tumor; Coculture Techniques; Cytotoxicity, Immunologic; genetics; Female; Interleukin-2; metabolism; Male; Mice; Mice, Inbred C57BL; Prostatic Neoplasms; Transfection
- From: National Journal of Andrology 2010;16(9):773-777
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo explore the anti-tumor immunity in vitro induced by prostate cancer cell vaccine transfected with recombinant adenovirus encoding 4-1BBL in mice.
METHODSThe replication-deficient adenovirus AdEasy-1 system was used to construct recombinant adenovirus Ad-m4-1BBL and Ad-eGFP. The prostate cancer cell RM-1 of mice was transfected with Ad-m4-1BBL and Ad-eGFP, and treated with mitomycin (MMC) to produce TCV, TCV-Ad-eGFP and TCV-Ad-m4-1BBL, followed by co-culture with syngeneic murine spleen cells. Then the cytotoxic activity of the lymphocytes against RM-1 cells was analyzed with CCK-8 solution, and IL-2 and INF-gamma were detected by ELISA.
RESULTSThe 4-1BBL protein was highly expressed in the TCV-Ad-m4-1BBL of the 4-1BBL-transfected mice. TCV-Ad-m4-1BBL significantly increased the expressions of IL-2 ([180.24 +/- 2.22] pg/ml) and INF-gamma ([1512.46 +/- 23.64] pg/ml) as compared with TCV and TCV-Ad-eGFP (P < 0.05), and induced higher RM-1 cell specific cytotoxicity ([34.24 +/- 2.64]%) than the latter two ([9.82 +/- 1.48]%) and ([14.65 +/- 3. 21]%), (P < 0.05). But none of them exhibited significant cytotoxicity against hepatocellular carcinoma Hepal-6.
CONCLUSIONThe m4-1BBL-expressing prostate cancer cell vaccine can effectively induce anti-tumor immune responses.
